Huang, Shyhmin <br/><br/>
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.  [electronic resource] 

 -  Cancer research  Aug 2004 
 - 5355-62 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0008-5472 
<br/><br/><label>Standard No.: </label>10.1158/0008-5472.CAN-04-0562  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Apoptosis--drug effects<br/>Carcinoma, Non-Small-Cell Lung--drug therapy<br/>Carcinoma, Squamous Cell--drug therapy<br/>Cell Division--drug effects<br/>Cetuximab<br/>Enzyme Inhibitors--pharmacology<br/>ErbB Receptors--antagonists & inhibitors<br/>Erlotinib Hydrochloride<br/>Female<br/>Flow Cytometry<br/>Gefitinib<br/>Head and Neck Neoplasms--drug therapy<br/>Humans<br/>Immunoblotting<br/>Lung Neoplasms--drug therapy<br/>Male<br/>Mice<br/>Mitogen-Activated Protein Kinases--metabolism<br/>Phosphorylation--drug effects<br/>Proliferating Cell Nuclear Antigen--metabolism<br/>Prostatic Neoplasms--drug therapy<br/>Protein Serine-Threonine Kinases--metabolism<br/>Protein-Tyrosine Kinases--antagonists & inhibitors<br/>Proto-Oncogene Proteins--metabolism<br/>Proto-Oncogene Proteins c-akt<br/>Quinazolines--administration & dosage<br/>Transplantation, Heterologous<br/>Tumor Cells, Cultured